Angeliq®: New hormonal therapy of the menopause, with antialdosterone and antiandrogenic properties;Angeliq®: Nouvelle hormonothérapie de la ménopause comportant des propriétés antialdostérone et antiandrogéniques

Revue Medicale de Liege

Volumn 59, Issue 3, 2004, Pages 162-166

  Gaspard, U ^a   Van Den Brule F ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antialdosterone; Antiandrogen; Drospirenone; Hormone replacement therapy; Menopause

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIANDROGEN; CHOLESTEROL; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; TRIMEGESTONE; ANDROSTANE DERIVATIVE; ESTRADIOL DROSPIRENONE COMBINATION; ESTRADIOL-DROSPIRENONE COMBINATION;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; METABOLIC PARAMETERS; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; THROMBOEMBOLISM; DRUG COMBINATION; REVIEW;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE;

EID: 3242878993     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Vestergaard P, Hermann AP, Stilgren L, et al.-Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure - a randomised controlled study. Maturitas, 2003, 46, 123-132.
2. Grady D, Herrington D, Bittner V, et al.-Cardiovascular disease outcomes during 6-8 years of hormone therapy. JAMA, 2002, 288, 49-57.
3. Writing group for the Women's Health Initiative Investigators.-Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results of the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-33.
4. "NIH asks participants in Women's Health Initiative estrogen-alone study to stop study pills, begin follow-up phase". Communication of NHLBI (USA) March 2, 2004.
5. Oger E, Alhenc-Gelas M, Lacut K, et al.-Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women. Arterioscler Thromb Vasc Biol, 2003, 23, 1671-1676.
6. Million Women Study Collaborators.-Breast cancer and hormone replacement therapy in the million women study. Lancet, 2003, 362, 419-427.
7. Elger W, Beier S, Pollow K, et al.-Conception and pharmacodynamic profile of drospirenone. Steroids, 2003, 68, 891-905.
8. Oelkers W.-Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contr Reprod Health Care, 2000, 5 (suppl 3), 17-24.
9. RALES investigators.-The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 1999, 341, 709-717.
10. Williams GH.-Cardiovascular benefits of aldosterone receptor antagonists. Climacteric, 2003, 6 (suppl.3), 29-35.
11. Krattenmacher R.-Drospirenone: pharmacology and pharmaco-kinetics of a unique progestogen. Contraception, 2000, 62, 29-38.
12. Data on file, Angeliq®, Schering AG, Berlin, 2003.
13. Rübig A.-Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric, 2003, 6 (suppl 3), 49-54.
14. Lobo RA, Whitehead MI.-Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric, 2001, 4, 110-119.
15. Lees B, Stevenson JC.-The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17beta and dydrogesterone. Osteoporosis Int, 2001, 12, 251-258.
16. Levy D, Larson MG, Vasan RS, et al.-The progression from hypertension to congestive heart failure. JAMA, 1996, 276, 1557-1562.
17. American Heart Association.-2002 Heart and Stroke statistical update. Dallas, Texas: American Heart Association, 2001.
18. Van de Weijer PHM, Barentsen R, de Vries MH.-Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol, 1999, 93, 551-557.